Giovana Radomille Tofoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Giovana Radomille Tofoli has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Cíntia M. S. Cereda
Department of Biochemistry, State University of Campinas, Institute of Biology , Campinas, São Paulo
1 shared publicationDaiane Quaglio
CORE, Laboratory of Clinical Analysis , Bragança Paulista, São Paulo
1 shared publication- Daniele Ribeiro de Araujo
Department of Biophysics, Universidade Federal de São Paulo, São Paulo 04021-001, SP, Brazil
1 shared publication - Eneida de Paula
Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas-SP, Brazil
1 shared publication Fabio Alessandro Proença Barros
CORE, Laboratory of Clinical Analysis , Bragança Paulista, São Paulo
1 shared publication- Francisco Carlos Groppo
Department of Biosciences, Faculdade de Odontologia de Piracicaba (FOP), Universidade Estadual de Campinas (UNICAMP), Piracicaba, SP, Brazil
1 shared publication
Latest Publications
- 16 December 2011
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 64 (3) , 397-403
Pharmacokinetic study of liposome-encapsulated and plain mepivacaine formulations injected intra-orally in volunteers
Objectives The pharmacokinetics of commercial and liposome‐encapsulated mepivacaine (MVC) injected intra‐orally in healthy volunteers was studied. Methods In this double blind, randomized cross‐over study, 15 volunteers received, at four different sessions, 1.8 ml of the following formulations: 2% MVC with 1 : 100 000 epinephrine (MVC2%EPI), 3% MVC (MVC3%), 2% and 3% liposome‐encapsulated MVC (MVC2%LUV and MVC3%LUV). Blood samples were collected pre dose (0 min) and at 15, 30, 45, 60, 90, 120, 180, 240, 300, 360 min after injections. Liquid chromatography‐tandem mass spectrometry was used to quantify plasma MVC concentrations. Results Pharmacokinetic analysis showed that the maximum plasma concentration (Cmax) and the areas under the curves (AUC0–360 and AUC0–∞) after MVC2%LUV and MVC2%EPI injections were smaller (P < 0.05) than the equivalent figures for MVC3% and MVC3%LUV. The time to maximum plasma concentration (Tmax) and the half‐life of elimination (t½beta) obtained after the treatment with MVC2%LUV, MVC2%EPI, MVC3% and MVC3%LUV presented no statistically significant differences (P > 0.05). Cmax, AUC0–360 and AUC0‐∞ after injection of the 2% formulations (MVC2%LUV and MVC2%EPI) did not exhibit statistically significant differences (P > 0.05). The pharmacokinetics of MVC2%LUV were comparable to the pharmacokinetics of MVC2%EPI. Conclusion The liposomal formulation of 2% MVC exhibits similar systemic absorption to the local anesthetic with vasoconstrictor.
- 16 December 2011
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 64 (3) , 397-403
Pharmacokinetic study of liposome-encapsulated and plain mepivacaine formulations injected intra-orally in volunteers
Objectives The pharmacokinetics of commercial and liposome‐encapsulated mepivacaine (MVC) injected intra‐orally in healthy volunteers was studied. Methods In this double blind, randomized cross‐over study, 15 volunteers received, at four different sessions, 1.8 ml of the following formulations: 2% MVC with 1 : 100 000 epinephrine (MVC2%EPI), 3% MVC (MVC3%), 2% and 3% liposome‐encapsulated MVC (MVC2%LUV and MVC3%LUV). Blood samples were collected pre dose (0 min) and at 15, 30, 45, 60, 90, 120, 180, 240, 300, 360 min after injections. Liquid chromatography‐tandem mass spectrometry was used to quantify plasma MVC concentrations. Results Pharmacokinetic analysis showed that the maximum plasma concentration (Cmax) and the areas under the curves (AUC0–360 and AUC0–∞) after MVC2%LUV and MVC2%EPI injections were smaller (P < 0.05) than the equivalent figures for MVC3% and MVC3%LUV. The time to maximum plasma concentration (Tmax) and the half‐life of elimination (t½beta) obtained after the treatment with MVC2%LUV, MVC2%EPI, MVC3% and MVC3%LUV presented no statistically significant differences (P > 0.05). Cmax, AUC0–360 and AUC0‐∞ after injection of the 2% formulations (MVC2%LUV and MVC2%EPI) did not exhibit statistically significant differences (P > 0.05). The pharmacokinetics of MVC2%LUV were comparable to the pharmacokinetics of MVC2%EPI. Conclusion The liposomal formulation of 2% MVC exhibits similar systemic absorption to the local anesthetic with vasoconstrictor.